Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Dupixent (dupilumab) Interleukin-4 receptor alpha antagonist Treatment of patients aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.

Too much earwax can cause rubbing of the ear or poking in the canal. A piece of ear wax can become dry and hard in the ear canal. This creates a feeling that an object is in the ear. Complete blockage ...

For people with diabetes who inject insulin, the syringe and needle size can make a big difference in comfort and staying on track with steady blood sugar levels. According to a 2024 statistics ...

With these label enhancements and anticipated approval of the prefilled syringe, we expect to see an acceleration in EYLEA HD demand. And now to Dupixent. In the first quarter, Dupixent achieved ...

it also issued two Complete Response Letters — one for the pre-filled syringe format and another rejecting extended dosing intervals beyond 16 weeks. Separately, Dupixent gained U.S. approval ...

Dupixent Global Net Sales ... The FDA issued a complete response letter for the EYLEA HD prefilled syringe, delaying its approval and impacting potential sales growth. Regeneron Pharmaceuticals ...

The officer then found a blue straw piece with white powder residue under the passenger side of the bench seat and two used syringes inside a black backpack next to Lazaro’s purse, the report said.

Dupixent’s sales increased 19% year over ... for the Eylea HD pre-filled syringe. The CRL was mostly issued due to a third-party component supplier. The FDA also issued a CRL to the sBLA for ...

Dupixent continued to show robust growth ... Regulatory delays impacting EYLEA HD’s pre-filled syringe approval could hinder adoption. Increased market share of off-label Avastin poses a ...